US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Addex Therapeutics

< Previous 1 2 3 Next >
News headline image
Addex Therapeutics Announces Executive Management Changes
From Addex Therapeutics
Via GlobeNewswire
News headline image
Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update
From Addex Therapeutics
Via GlobeNewswire
News headline image
Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior
From Addex Therapeutics
Via GlobeNewswire
News headline image
Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026
From Addex Therapeutics
Via GlobeNewswire
News headline image
ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027
From Addex Therapeutics
Via GlobeNewswire
News headline image
Addex Convenes Annual General Meeting 2026
From Addex Therapeutics
Via GlobeNewswire
News headline image
Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness
From Addex Therapeutics
Via GlobeNewswire
News headline image
Addex Shareholders Approve All Resolutions at Annual General Meeting
From Addex Therapeutics
Via GlobeNewswire
News headline image
Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
From Addex Therapeutics
Via GlobeNewswire
News headline image
Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026
From Addex Therapeutics
Via GlobeNewswire
News headline image
Addex Reports Full Year 2025 Financial Results and Provides Corporate Update
From Addex Therapeutics
Via GlobeNewswire
News headline image
Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model
From Addex Therapeutics
Via GlobeNewswire
News headline image
Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026
From Addex Therapeutics
Via GlobeNewswire
News headline image
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model
From Addex Therapeutics
Via GlobeNewswire
News headline image
Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment
From Addex Therapeutics
Via GlobeNewswire
News headline image
Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia
From Addex Therapeutics
Via GlobeNewswire
News headline image
Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.
From Addex Therapeutics
Via GlobeNewswire
News headline image
Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update
From Addex Therapeutics
Via GlobeNewswire
News headline image
Addex Therapeutics to Report 2025 Third Quarter Financial Results And Host Conference Call on December 4, 2025
From Addex Therapeutics
Via GlobeNewswire
News headline image
Addex Increases Issued Share Capital to Create Treasury Shares
From Addex Therapeutics
Via GlobeNewswire
News headline image
Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update
From Addex Therapeutics
Via GlobeNewswire
News headline image
Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025
From Addex Therapeutics
Via GlobeNewswire
News headline image
Addex Appoints Bank of New York Mellon as Depositary Bank
From Addex Therapeutics
Via GlobeNewswire
News headline image
Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders
From Addex Therapeutics
Via GlobeNewswire
News headline image
Addex Shareholders Approve All Resolutions at Annual General Meeting
From Addex Therapeutics
Via GlobeNewswire
News headline image
Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update
From Addex Therapeutics
Via GlobeNewswire
News headline image
Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025
From Addex Therapeutics
Via GlobeNewswire
News headline image
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models
From Addex Therapeutics
Via GlobeNewswire
News headline image
Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cough Conference
From Addex Therapeutics
Via GlobeNewswire
News headline image
Addex Convenes Annual General Meeting 2025
From Addex Therapeutics
Via GlobeNewswire
< Previous 1 2 3 Next >